EcoDrugPlus

Gamma-Aminobutyric Acid (Gaba) A Receptor, Subunit Beta 3

Ensembl ID : ENSMSIG00000015876
Gene Symbol: GABRB3
1 Cross references
278 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Subunit Delta

Ensembl ID : ENSMSIG00000014206
Gene Symbol: GABRD
1 Cross references
208 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Subunit Gamma 1

Ensembl ID : ENSMSIG00000008710
Gene Symbol: GABRG1
1 Cross references
203 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Subunit Gamma 2

Ensembl ID : ENSMSIG00000022945
Gene Symbol: GABRG2
1 Cross references
219 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Subunit Gamma 3

Ensembl ID : ENSMSIG00000015743
Gene Symbol: GABRG3
1 Cross references
270 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Subunit Theta

Ensembl ID : ENSMSIG00000010315
Gene Symbol: GABRQ
1 Cross references
102 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 1

Ensembl ID : ENSMSIG00000015270
Gene Symbol: GABBR1
1 Cross references
279 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 2

Ensembl ID : ENSMSIG00000020884
Gene Symbol: GABBR2
1 Cross references
256 Possible Orthologues:

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSMSIG00000005108
Gene Symbol: GIPR
1 Cross references
108 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSMSIG00000014132
Gene Symbol: GCGR
1 Cross references
198 Possible Orthologues:

Glucagon-Like Peptide 1 Receptor

Ensembl ID : ENSMSIG00000011363
Gene Symbol: GLP1R
1 Cross references
148 Possible Orthologues:

Glucagon-Like Peptide 2 Receptor

Ensembl ID : ENSMSIG00000008045
Gene Symbol: GLP2R
1 Cross references
220 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).